


IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-11 (Canceled).

Claim 12 (New): A nitroimidazole derivative represented by the following formula

(1):



wherein R^1 represents a hydrogen atom or a C_1 - C_4 alkanoyl group; and X represents a fluorine atom or an isotope thereof.

Claim 13 (New): The nitroimidazole derivative according to claim 12, wherein X is ^{18}F .

Claim 14 (New): A diagnostic imaging agent comprising, as an active ingredient, a nitroimidazole derivative as recited in claim 12.

Claim 15 (New): A diagnostic imaging agent comprising, as an active ingredient, a nitroimidazole derivative as recited in claim 13.

Claim 16 (New): A method of diagnostic imaging comprising administration of a nitroimidazole derivative as recited in claim 12 for imaging.

Claim 17 (New): A method of diagnostic imaging comprising administration of a nitroimidazole derivative as recited in claim 13 for imaging.


Claim 18 (New): The method of diagnostic imaging according to claim 16, wherein an ischemic site or cancer cell is imaged.

Claim 19 (New): The method of diagnostic imaging according to claim 17, wherein an ischemic site or cancer cell is imaged.

Claim 20 (New): The method according to claim 18, wherein a cancer cell is imaged and wherein the cancer cell is a chemotherapeutic-agent-resistant or radiation-resistant cancer cell.


Claim 21 (New): The method according to claim 19, wherein a cancer cell is imaged and wherein the cancer cell is a chemotherapeutic-agent-resistant or radiation-resistant cancer cell.

Claim 22 (New): A nitroimidazole derivative represented by the following formula (2):



wherein R¹ represents a hydrogen atom or a C₁-C₄ alkanoyl group.

Claim 23 (New): A method for producing a nitroimidazole derivative as recited in claim 12, comprising fluorination of a nitroimidazole derivative represented by the following formula (2):



wherein R¹ represents a hydrogen atom or a C₁-C₄ alkanoyl group.

Claim 24 (New): The nitroimidazole derivative according to claim 12, wherein R¹ represents a hydrogen atom.

Claim 25 (New): The nitroimidazole derivative according to claim 12, wherein R¹ represents an acetyl group.

Claim 26 (New): The nitroimidazole derivative according to claim 13, wherein R¹ represents a hydrogen atom.

Claim 27 (New): The nitroimidazole derivative according to claim 13, wherein R¹ represents an acetyl group.

Claim 28 (New): The nitroimidazole derivative according to claim 12, which is 1-[2-fluoro(¹⁸F or ¹⁹F)-1-(hydroxymethyl)ethoxy]methyl-2-nitroimidazole or 1-[1-acetoxymethyl-2-fluoro(¹⁸F or ¹⁹F)ethoxy]methyl-2-nitroimidazole.

DISCUSSION OF THE AMENDMENT

All of the claims have been cancelled and replaced with new Claims 12-28. Claims 12 and 13 correspond to original Claims 1 and 2, respectively. Claims 14 and 15 correspond to original Claim 3. Claims 16 and 17 correspond to original Claim 8. Claims 18 and 19 correspond to original Claim 9. Claims 20 and 21 are supported by original Claim 5. Claims 22 and 23 correspond to original Claims 10 and 11, respectively. Claims 24 and 26 are supported in the specification at page 5, second and third lines from the bottom. Claims 25 and 27 are supported at page 5, fourth line from the bottom. Finally, Claim 28 is supported at page 6, lines 1-4.

No new matter has been added by the above amendment. Claims 12-28 are now pending in the application.